| Dyne Therapeutics | Phase 1/2 | $2.9B | Neuromuscular Diseases, Genetic Disorders |
| Third Harmonic Bio | Phase 1b | $240M | Allergy & Immunology, Inflammatory Diseases |
| Q32 Bio | Phase 2 | $89.9M | Autoimmune Diseases, Inflammatory Diseases |
| Convexia | preclinical | — | Neuroscience, Neurodegenerative Diseases |
| Eluminex Biosciences | phase-2 | — | Ophthalmology, Immunology |
| Auron Therapeutics | phase-1 | — | Oncology |
| NewBiologix | phase-1 | — | Rare Disease, Genetics & Genomics |
| Forward Therapeutics | preclinical | — | Immunology |
| Delphia Therapeutics | preclinical | — | Oncology |
| Pheon Therapeutics | preclinical | — | Oncology |
| Matchpoint Therapeutics | preclinical | — | Immunology |
| Pretzel Therapeutics | preclinical | — | Rare Disease, Metabolic Disorders |
| Accent Therapeutics | preclinical | — | Oncology |
| Initial Therapeutics | preclinical | — | Neuroscience, Rare Disease |
| MBrace | phase-1 | — | Oncology |
| Atalanta Therapeutics | preclinical | — | Neuroscience, Rare Disease |
| Lifordi Immunotherapeutics | Phase 1 | — | Autoimmune Disorders, Inflammatory Disorders |
| IFM Therapeutics (2) | Phase 2 | — | Oncology, Inflammatory Diseases |
| Rectify Pharmaceuticals | Pre-clinical | — | Hepatobiliary, Cardio-Renal-Metabolic |
| Renasant Bio | Pre-clinical | — | Nephrology, Genetic Disorders |
| Be Biopharma | Phase 1 | — | Rare Diseases, Hematology |
| TRexBio | Phase 1 | — | Immunology, Oncology |
| Ethris | Pre-clinical | — | Respiratory Diseases, Genetic Disorders |
| Homology Medicines | Phase 2 | — | Rare Genetic Diseases, Metabolic Disorders |
| Chroma Medicine | preclinical | — | Genetics & Genomics |
| Clasp Therapeutics | preclinical | — | Oncology, Immunology |
| Superluminal Medicines | preclinical | — | Neuroscience, Psychiatry |
| Obsidian Therapeutics | phase-1 | — | Oncology |
| Timberlyne Therapeutics | preclinical | — | Neuroscience, Psychiatry |
| Soufflé Therapeutics | phase-2 | — | Oncology, Immunology |
| ImmunoVax | phase-2 | — | Oncology, Immunology |
| CellForge | phase-2 | — | Oncology, Immunology |
| OncoTarget | phase-2 | — | Oncology |
| Nimbus Therapeutics | phase-2 | — | Immunology, Oncology |
| Vesalius Therapeutics | phase-1 | — | Metabolic, Cardiovascular |
| NeuroHeal | phase-2 | — | Neuroscience, Regenerative Medicine |
| OncoImmuno | phase-1 | — | Oncology, Immunology |
| Avenzo Therapeutics | phase-1 | — | Oncology |
| Aiolos Bio | phase-2 | — | Respiratory, Immunology |